ImmunityBio (IBRX) Other Non Operating Income (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Other Non Operating Income data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 80.14% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 170.44% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, up 42753.33% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1.1 million, down from $6.9 million in the prior quarter.
• Over the last five years, Other Non Operating Income for IBRX reached as high as $6.9 million in Q4 2025 and fell as low as -$20.1 million in Q4 2024.
• Historically, Other Non Operating Income has averaged -$507600.0 across 5 years, with a median of $6000.0 in 2022.
• Across the five-year window, Other Non Operating Income sank 26825.0% in 2023 and soared 27990.0% in 2025, its largest moves.
• Year by year, Other Non Operating Income stood at -$187000.0 in 2022, then plunged by 1088.77% to -$2.2 million in 2023, then slumped by 804.14% to -$20.1 million in 2024, then soared by 134.35% to $6.9 million in 2025, then tumbled by 83.95% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $1.1 million in Q1 2026, $6.9 million in Q4 2025, and $289000.0 in Q3 2025.